

2022

Nevada Medicaid Drug Use Review Board Meeting

April 28, 2022



silversummit
healthplan

Table of Contents

Clinical Presentation – Movement Disorder Agents – Austedo, Ingrezza - 3

Clinical Presentation – Sedative Hypnotics– Hetlioz - 7

Clinical Presentation – Monoclonal Antibodies for the Treatment of Respiratory
Conditions – Antiasthmatic Monoclonal Antibodies - 10

Clinical Presentation – Vuity (pilocarpine) - Vuity - 14

DUR Board Requested Reports – Opioid Trend - 17

Standard DUR Reports – 22

Movement Disorder Agents

Clinical Presentations



silversummit
healthplan

DRUG USE REVIEW BOARD

MCO PRIOR AUTHORIZATION CRITERIA REVIEW FORM

Clinical criteria for drugs or drug classes listed on the appropriate agenda, will be presented at the quarterly Drug Use Review Board meetings. This form will allow Managed Care Organizations to approve or disapprove the proposed criteria and suggest changes to be supported at the quarterly meeting.

DUR Meeting Date: April 28, 2022

Prior Authorization Criteria being reviewed: Austedo

Managed Care Organization name: SilverSummit HealthPlan

Please place a check mark in the appropriate box:

- I approve the criteria as presented by OptumRx
- I disapprove of the criteria as presented by OptumRx

I recommend the following changes to the criteria as presented. Please be brief and identify the section of the proposed criteria. If you feel you need more space for proposed changes, you may attach a word document, with only the suggested changes to criteria being presented.

You will have an opportunity to support the recommended changes at the time of the Drug Use Review Board quarterly meeting.

If this form is not completed and returned to the policy specialist with DHCFP by the designated deadline, the assumption will be made that you approve all prior authorization criteria as presented.

Please print the name of the individual completing this form: Tom Beranek

Signature of individual completing this form: Tom Beranek

DRUG USE REVIEW BOARD

MCO PRIOR AUTHORIZATION CRITERIA REVIEW FORM

Clinical criteria for drugs or drug classes listed on the appropriate agenda, will be presented at the quarterly Drug Use Review Board meetings. This form will allow Managed Care Organizations to approve or disapprove the proposed criteria and suggest changes to be supported at the quarterly meeting.

DUR Meeting Date: April 28, 2022

Prior Authorization Criteria being reviewed: Ingrezza

Managed Care Organization name: SilverSummit HealthPlan

Please place a check mark in the appropriate box:

I approve the criteria as presented by OptumRx

I disapprove of the criteria as presented by OptumRx

I recommend the following changes to the criteria as presented. Please be brief and identify the section of the proposed criteria. If you feel you need more space for proposed changes, you may attach a word document, with only the suggested changes to criteria being presented.

You will have an opportunity to support the recommended changes at the time of the Drug Use Review Board quarterly meeting.

If this form is not completed and returned to the policy specialist with DHCFP by the designated deadline, the assumption will be made that you approve all prior authorization criteria as presented.

Please print the name of the individual completing this form: Tom Beranek

Signature of individual completing this form: Tom Beranek


Movement Disorder Drug Therapy

Summary of Utilization

January 1, 2021 to December 31, 2021

SilverSummit Healthplan

Product Name		Count of Members	Count of Claims	Sum of Qty	Sum of Days
AUSTEDO	TAB 12MG	7	7	780	210
INGREZZA	CAP 40MG	5	5	150	150
INGREZZA	CAP 60MG	2	2	60	60
INGREZZA	CAP 80MG	14	15	450	450
Total		28	29	1,440	870



Sedative Hypnotics

Clinical Presentations



silversummit
healthplan

DRUG USE REVIEW BOARD

MCO PRIOR AUTHORIZATION CRITERIA REVIEW FORM

Clinical criteria for drugs or drug classes listed on the appropriate agenda, will be presented at the quarterly Drug Use Review Board meetings. This form will allow Managed Care Organizations to approve or disapprove the proposed criteria and suggest changes to be supported at the quarterly meeting.

DUR Meeting Date: April 28, 2022

Prior Authorization Criteria being reviewed: Hetlioz

Managed Care Organization name: SilverSummit HealthPlan

Please place a check mark in the appropriate box:

- I approve the criteria as presented by OptumRx
- I disapprove of the criteria as presented by OptumRx

I recommend the following changes to the criteria as presented. Please be brief and identify the section of the proposed criteria. If you feel you need more space for proposed changes, you may attach a word document, with only the suggested changes to criteria being presented.

You will have an opportunity to support the recommended changes at the time of the Drug Use Review Board quarterly meeting.

If this form is not completed and returned to the policy specialist with DHCFP by the designated deadline, the assumption will be made that you approve all prior authorization criteria as presented.

Please print the name of the individual completing this form: Tom Beranek

Signature of individual completing this form: Tom Beranek

TESIMELTEON
Summary of Utilization
January 1, 2021 to December 31, 2021
SilverSummit Healthplan

No Utilization For This Time Period

Monoclonal
Antibodies for the
Treatment of
Respiratory
Conditions

Clinical Presentations



DRUG USE REVIEW BOARD

MCO PRIOR AUTHORIZATION CRITERIA REVIEW FORM

Clinical criteria for drugs or drug classes listed on the appropriate agenda, will be presented at the quarterly Drug Use Review Board meetings. This form will allow Managed Care Organizations to approve or disapprove the proposed criteria and suggest changes to be supported at the quarterly meeting.

DUR Meeting Date: April 28, 2022

Prior Authorization Criteria being reviewed: Monoclonal Antibodies

Managed Care Organization name: SilverSummit HealthPlan

Please place a check mark in the appropriate box:

- I approve the criteria as presented by OptumRx
- I disapprove of the criteria as presented by OptumRx

I recommend the following changes to the criteria as presented. Please be brief and identify the section of the proposed criteria. If you feel you need more space for proposed changes, you may attach a word document, with only the suggested changes to criteria being presented.

You will have an opportunity to support the recommended changes at the time of the Drug Use Review Board quarterly meeting.

If this form is not completed and returned to the policy specialist with DHCFP by the designated deadline, the assumption will be made that you approve all prior authorization criteria as presented.


Please print the name of the individual completing this form: Tom Beranek

Signature of individual completing this form: Tom Beranek

ANTIASTHMATIC - MONOCLONAL ANTIBODIES


Summary of Utilization
 January 1, 2021 to December 31, 2021
 SilverSummit Healthplan

Product Name	Count of Members	Count of Claims	Sum of Qty	Sum of Days
FASENRA INJ 30MG/ML	13	13	13	644
NUCALA INJ 100MG	3	3	3	84
NUCALA INJ 100MG/ML	28	32	32	904
XOLAIR INJ 150MG/ML	104	108	227	3,024
XOLAIR INJ 75/0.5	7	9	9	252
XOLAIR SOL 150MG	13	13	78	364
Total	168	178	362	5,272



DUPILUMAB
Summary of Utilization
January 1, 2021 to December 31, 2021
SilverSummit Healthplan

Product Name		Count of Members	Count of Claims	Sum of Qty	Sum of Days
DUPIXENT	INJ 200/1.14	13	16	36.48	420
DUPIXENT	INJ 200MG	1	2	9.12	56
DUPIXENT	INJ 300/2ML	129	141	564	3,898
Total		143	159	609.60	4,374



Vuity (pilocarpine)

Clinical Presentations



silversummit
healthplan

DRUG USE REVIEW BOARD

MCO PRIOR AUTHORIZATION CRITERIA REVIEW FORM

Clinical criteria for drugs or drug classes listed on the appropriate agenda, will be presented at the quarterly Drug Use Review Board meetings. This form will allow Managed Care Organizations to approve or disapprove the proposed criteria and suggest changes to be supported at the quarterly meeting.

DUR Meeting Date: April 28, 2022

Prior Authorization Criteria being reviewed: Vuity

Managed Care Organization name: SilverSummit HealthPlan

Please place a check mark in the appropriate box:

I approve the criteria as presented by OptumRx

I disapprove of the criteria as presented by OptumRx

I recommend the following changes to the criteria as presented. Please be brief and identify the section of the proposed criteria. If you feel you need more space for proposed changes, you may attach a word document, with only the suggested changes to criteria being presented.

You will have an opportunity to support the recommended changes at the time of the Drug Use Review Board quarterly meeting.

If this form is not completed and returned to the policy specialist with DHCFP by the designated deadline, the assumption will be made that you approve all prior authorization criteria as presented.

Please print the name of the individual completing this form: Tom Beranek

Signature of individual completing this form: Tom Beranek

VUITY
Summary of Utilization
January 1, 2021 to December 31, 2021
SilverSummit Healthplan

No Utilization For This Time Period

Opioid Trend –
Top Prescribers
and Members

Board Requested
Reports



Opioid Utilization
Overall Summary
January 1, 2021 to December 31, 2021
SilverSummit Healthplan

Year Month Filled	Member Count	Claim Count	Claims per Member	Sum of Days Supply	Sum of Qty	Qty per Member	MME/ DaySupply/ Member
202101	1,245	1,395	1.12	28,858	93,340	74.97	40.5
202102	1,196	1,353	1.13	28,263	92,259	77.14	42.2
202103	1,346	1,576	1.17	31,951	102,292	76.00	42.3
202104	1,327	1,526	1.15	30,848	101,794	76.71	42.5
202105	1,318	1,469	1.11	28,792	96,073	72.89	40.3
202106	1,326	1,496	1.13	30,333	99,662	75.16	40.5
202107	1,250	1,418	1.13	27,989	91,620	73.30	41.0
202108	1,288	1,461	1.13	29,363	96,289	74.76	40.5
202109	1,306	1,480	1.13	29,903	98,266	75.24	40.1
202110	1,288	1,456	1.13	28,553	93,281	72.42	38.5
202111	1,238	1,393	1.13	27,719	91,591	73.98	39.3
202112	1,250	1,406	1.12	28,243	90,504	72.40	39.3

Top 10 Opioid Prescribers by Count of Claims

SilverSummit Healthplan

Q4 2021

Encrypted ID	Specialty	Degree	City	Member Count	Claim Count	Sum of Day Supply	Sum of Qty	MME/ Day Supply / Member
Z1	Pain Management	NP	Las Vegas	49	145	4,181	12,965	104.9
FFF	Pain Management	PA	Las Vegas	52	135	3,958	12,596	96.3
Q1	Pain Management	FNP-C	Las Vegas	56	132	3,765	11,989	80.40
CC	Pain Management	MD	Las Vegas	70	99	2,759	8,912	54.5
M2	Pain Management	PA-C	Las Vegas	35	78	2,250	6,689	81.6
G	Anesthesiology	MD	Las Vegas	33	74	2,022	6,255	89.8
Y	Pain Management	MD	Las Vegas	32	74	2,149	6,052	73.5
I3	Pain Management	PA	N Las Vegas	32	70	2,068	6,864	82.4
AA	Pain Management	MD	Las Vegas	42	58	1,709	5,228	61.8
E	Pain Management	PA	Las Vegas	24	48	1,440	5,070	122.1

Q3 2021

Encrypted ID	Specialty	Degree	City	Member Count	Claim Count	Sum of Day Supply	Sum of Qty	MME/ Day Supply / Member
Z1	Pain Management	NP	Las Vegas	57	143	4,227	13,136	88.6
Q1	Pain Management	FNP-C	Las Vegas	58	141	4,037	13,027	82.6
FFF	Pain Management	PA	Las Vegas	46	136	3,963	12,687	111.20
F	Pain Management	PA	Las Vegas	32	102	2,915	9,226	166.8
E	Pain Management	PA	Las Vegas	43	91	2,547	8,976	102.5
J	Pain Management	PA	Las Vegas	29	88	2,514	8,076	120.8
CC	Pain Management	MD	Las Vegas	61	88	2,513	7,719	56.0
G	Anesthesiology	MD	Las Vegas	28	66	1,881	5,509	90.9
M2	Pain Management	PA-C	Las Vegas	33	61	1,789	5,440	70.1
Y	Pain Management	MD	Las Vegas	24	60	1,754	5,172	82.8

Opioid Utilization by Member

Top 10 Members by Claim Count

Current Quarter

SilverSummit Healthplan

Member Enc ID	Enc NPI	Count of Claim	Sum of Qty	Sum of Days	MME/ DaySupply/ Member
1		7	512	173	150.00
	G	11	512	173	150.00
2		7	660	210	121.00
	C3	6	540	180	121.00
	B4	1	120	30	40.00
3		7	660	210	90.00
	C4	3	300	90	90.00
	D	2	180	60	90.00
	H2	2	180	60	90.00
4		7	402	201	45.00
	Z1	7	402	201	45.00
5		7	450	210	60.00
	FFF	5	330	150	60.00
	CC	2	120	60	60.00
6		7	750	210	195.00
	Z3	7	750	210	195.00
7		7	510	210	260.00
	Y3	7	510	210	260.00
8		7	282	67	31.50
	A4	7	282	67	31.50
9		7	540	210	90.00
	M	5	390	150	90.00
	W3	2	150	60	90.00
10		7	660	210	120.00
	X3	7	660	210	120.00
Grand Total		70	5,426	1,911	1,162.50

Opioid Utilization by Member
Top 10 Members by Claim Count
Current Quarter
SilverSummit Healthplan

Member Enc ID	Count of Claim	Sum of Qty	Sum of Days
1	7	512	173
MORPHINE SUL TAB 30MG ER	4	180	90
OXYCODONE TAB 15MG	3	332	83
2	7	660	210
XTAMPZA ER CAP 27MG	3	180	90
HYDROCO/APAP 10-325MG	4	480	120
3	7	660	210
MORPHINE SUL TAB 15MG ER	3	180	90
OXYCOD/APAP 10-325MG	4	480	120
4	7	402	201
MORPHINE SUL TAB 15MG ER	4	222	111
OXYCOD/APAP 5-325MG	3	180	90
5	7	450	210
MORPHINE SUL TAB 15MG ER	3	90	90
OXYCOD/APAP 10-325MG	4	360	120
6	7	750	210
OXYCODONE TAB 15MG	4	720	120
FENTANYL DIS 25MCG/HR	3	30	90
7	7	510	210
HYDROCO/APAP 10-325MG	4	240	120
METHADONE TAB 10MG	3	270	90
8	7	282	67
HYDROCO/APAP TAB 7.5-325	7	282	67
9	7	540	210
HYDROCO/APAP 10-325MG	4	360	120
MORPHINE SUL TAB 30MG ER	3	180	90
10	7	660	210
OXYCODONE TAB 10MG	4	480	120
MORPHINE SUL TAB 30MG ER	3	180	90
Grand Total	70	5,426	1,911

Standard DUR
Reports



Top 10 Therapeutic Classes

SilverSummit Healthplan
October 1, 2021 to December 31, 2021

Top 10 Drug Classes by Paid Amount

2021 Q4	Drug Class Name	Count of Claims	Pharmacy Paid
	Antiretrovirals	1148	SSHP Confidential
	Insulin	1907	SSHP Confidential
	Incretin Mimetic Agents (GLP-1 Receptor Agonists)	986	SSHP Confidential
	Antipsychotics - Misc.	613	SSHP Confidential
	Anti-TNF-alpha - Monoclonal Antibodies	75	SSHP Confidential
	Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors	738	SSHP Confidential
	Sympathomimetics	6239	SSHP Confidential
	Antineoplastic Enzyme Inhibitors	28	SSHP Confidential
	Viral Vaccine	8036	SSHP Confidential
	Direct Factor Xa Inhibitors	729	SSHP Confidential

2021 Q3	Drug Class Name	Count of Claims	Pharmacy Paid
	Antiretrovirals	1058	SSHP Confidential
	Insulin	1816	SSHP Confidential
	Incretin Mimetic Agents (GLP-1 Receptor Agonists)	893	SSHP Confidential
	Anti-TNF-alpha - Monoclonal Antibodies	86	SSHP Confidential
	Antipsychotics - Misc.	592	SSHP Confidential
	Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors	682	SSHP Confidential
	Sympathomimetics	5682	SSHP Confidential
	Antipsoriasis	46	SSHP Confidential
	Direct Factor Xa Inhibitors	689	SSHP Confidential
	Antineoplastic Enzyme Inhibitors	30	SSHP Confidential

Top 10 Drug Classes by Claim Count

2021 Q4	Drug Class Name	Count of Claims	Pharmacy Paid
	Viral Vaccines	8036	SSHP Confidential
	Nonsteroidal Anti-inflammatory Agents (NSAIDs)	7050	SSHP Confidential
	HMG CoA Reductase Inhibitors	6817	SSHP Confidential
	Sympathomimetics	6239	SSHP Confidential
	Selective Serotonin Reuptake Inhibitors (SSRIs)	6014	SSHP Confidential
	Anticonvulsants - Misc.	5672	SSHP Confidential
	Proton Pump Inhibitors	3729	SSHP Confidential
	Antianxiety Agents - Misc.	3368	SSHP Confidential
	Central Muscle Relaxants	3339	SSHP Confidential
	Antihistamines - Non-Sedating	3167	SSHP Confidential

2021 Q3	Drug Class Name	Count of Claims	Pharmacy Paid
	Viral Vaccines	8087	SSHP Confidential
	Nonsteroidal Anti-inflammatory Agents (NSAIDs)	6987	SSHP Confidential
	HMG CoA Reductase Inhibitors	6577	SSHP Confidential
	Sympathomimetics	5682	SSHP Confidential
	Selective Serotonin Reuptake Inhibitors (SSRIs)	5655	SSHP Confidential
	Anticonvulsants - Misc.	5514	SSHP Confidential
	Proton Pump Inhibitors	3587	SSHP Confidential
	Central Muscle Relaxants	3335	SSHP Confidential
	Opioid Combinations	3179	SSHP Confidential
	Antianxiety Agents - Misc.	3170	SSHP Confidential

Prospective DUR

SilverSummit Healthplan

October 1, 2021 to December 31, 2021

Prospective DUR							
What percentage of claims denied at Point of Sale for the following DUR edits?	Total Alerts	Total Alert Overrides	% Alert Overrides	Total Alert Cancels	% Alert Cancels	Total Alerts not adjudicated	% Alerts not adjudicated
Early Refill (ER)	20,180	0	0%	0	0%	20,180	100%
Therapeutic Duplication (TD)	26,089	7,032	27%	2,498	10%	16,559	63%
Ingredient Duplication (ID)	15,749	0	0%	0	0%	15,749	100%
Late Refill (LR)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total High Dose (HD)	2,358	1,417	60%	578	25%	363	15%
Drug-Pregnancy (PG)	47	28	60%	17	36%	2	4%
Total Low Dose (LD)	4,461	2,936	66%	842	19%	683	15%
Drug-Drug (DD)	12,952	9,130	70%	1,449	11%	2,373	18%
Drug-Disease (MC)	2,174	1,502	69%	305	14%	367	17%
Drug-Allergy (DA)	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Drug-Age (PA)	28	20	71%	4	14%	4	14%

Top 10 Drugs by Therapeutic Problem Type										
ER	TD	ID	LR	HD	PG	LD	DD	MC	DA	PA
Albuterol Sulfate	Albuterol Sulfate	Albuterol Sulfate	N/A	Cefdinir	Atorvastatin	Cholecaliferol	Buprenorphine Hcl - Naloxone Hcl Dihydrate	Alprazolam	N/A	Diphenhydramine
Amlodipine	Amlodipine	Amlodipine Besylate	N/A	Ergocalciferol	Conjugated Estrogens - Medroxyprogesterone Acetate	COVID-19 (SARS-COV-2) MRNA Virus Vaccine	Buspirone	Amphetamine-Dextroamphetamine	N/A	Nitrofurantoin
Atorvastatin	Atorvastatin	Atorvastatin	N/A	Famotidine	Levonorgestrel (Emergency OC)	Ergocalciferol	Escitalopram	Bupropion	N/A	Promethazine - DM
Gabapentin	Bupropion Hcl	Gabapentin	N/A	Ibuprofen	Medroxyprogesterone Acetate	Norelgestromin-Ethinyl Estradiol	Fluoxetine	Gabapentin	N/A	Promethazine HCL
Lisinopril	Gabapentin	Metformin	N/A	Meloxicam	Norethindrone (Contraceptive)	Ondansetron Hcl	Ibuprofen	Glipizide	N/A	N/A
Metformin	Levothyroxine	Sertraline	N/A	N/A	Prenatal Vit W/Ferrous Fumarate- Folic Acid	Potassium Chloride Microencapsulated Crystals ER	Sertraline	Insulin Glargine	N/A	N/A
Sertraline	Metformin	Trazodone	N/A	N/A	N/A	Propranolol HCL	Trazodone	Norethin Acet & Estrad-Fe	N/A	N/A
N/A	Sertraline	N/A	N/A	N/A	N/A	N/A	N/A	Norelgestromate-Ethinyl Estradiol (Triphasic)	N/A	N/A

Retrospective DUR

SilverSummit Healthplan

October 1, 2021 to December 31, 2021

Retrospective DUR							
Topic	Description of Intervention	Type of Contact (Media)	Number of Contacts	Number of Responses	Response Rate	Provider Targeted (e.g, Physician, Pharmacist)	Performed by (e.g., Subcontractor, etc.)
Drug Age Contraindication	Outreach to prescribers for member's identified with a claim for a medication on the Beers Criteria Medication List.	Mail	9	0	0%	Physician	SSHP
Drug Disease Contraindication	Outreach to prescribers for member's identified with claims for both anti-dementia and antipsychotic medications.	Mail	4	1	25%	Physician	SSHP
MME Benchmark	Provider outreach for members who are using opioids at doses greater than or equal to 120mg of morphine per day (cancer and sickle cell patients are excluded).	Mail	54	9	17%	Physician	SSHP
Diabetes Underuse	Provider targeted outreach for members with diabetes and hypertension, who are not optimizing therapy with an ACEI or ARB for prevention of nephropathy.	Mail	151	7	5%	Physician	SSHP
Antiepileptic Adherence	Outreach to members who are non-adherent on their Antiepileptic Medications.	Phone/Mail	247	42	17%	Member	SSHP

Retrospective DUR

SilverSummit Healthplan

January 1, 2021 to December 31, 2021

Problem, Goal and Intervention Outcomes				
Description	Goal Description	Achieved	Not Achieved	No Longer Relevant
Opioid Overuse	Improve Regimen	8	2	1
Dangerous 3 Drug Combination	Discountinue Drug	9	9	1
Dangerous 2 Drug Combination	Discountinue Drug	113	147	8
Benzodiazepine Overuse	Discountinue Drug	130	442	46
Proton Pump Inhibitor Overuse	Discountinue Drug	237	534	58
Antibiotic Overuse	Discountinue Drug	48	24	1
Non-benzopdiapepine Hypnotic Overuse	Discountinue Drug	58	113	11
Asthmatics without a controller	Add controller Agent in Asthma	40	190	22
Diabetes without ACE/ARB	Add ACE/ARB in Diabetes	43	132	31
Diabetes without a statin	Add Statin in Diabetes	124	265	61
All Therapeutic Duplication	Remove Duplicated Drug	362	113	27